The Real Picture

The Truth About Peptides

Peptides have a reputation problem. Most of it is wrong. Here's what the data actually says — from FDA approvals to clinical trials to market scale.

80+
FDA-approved peptide drugs
$100B
GLP-1 market projected by 2030
150+
peptides in active clinical trials
100yrs
of therapeutic use — insulin since 1921
Want to know which ones are right for you? Build your protocol →
8 myths. 8 facts.
Setting the record straight
These are the most common things people get wrong about peptides — and what the data actually shows.
Peptides are illegal
80+ peptide drugs are FDA-approved. 14 more being restored to legal compounding access in 2026.
The FDA has approved over 80 therapeutic peptides. Insulin, Ozempic, and dozens of cancer treatments are all peptides — well within the law.
Peptides are just steroids
Completely different compounds. Peptides signal your body's natural processes. Steroids override your endocrine system.
Peptides are amino acid chains that bind to surface receptors. Steroids are lipid-based and alter gene expression directly — a fundamentally different mechanism with a far higher risk profile.
Peptides are unnatural / synthetic
Your body produces thousands of peptides. Insulin, oxytocin, and glucagon are all peptides you already make.
Peptide therapy works by supplementing or stimulating biological processes already happening in your body — not introducing foreign chemistry.
Only for athletes and bodybuilders
FDA-approved peptides treat diabetes, cancer, osteoporosis, infertility, and obesity. 1 in 8 Americans has already used one.
GLP-1 agonists alone are projected to reach $100 billion in annual sales by 2030 — driven by metabolic health, not athletics.
New, experimental, unproven
Insulin — a peptide — has been in clinical use since 1921. Over 100 years of therapeutic history.
34 peptide drugs were approved between 2016 and 2026 alone. The pipeline is accelerating, not beginning.
Peptides cause severe side effects
Most clinical peptides produce minor side effects — typically temporary injection site reactions.
The risk profile of therapeutic peptides is significantly milder than steroids, most small-molecule drugs, and many OTC medications. Context and sourcing always matter.
All peptides are the same
150+ peptides are in active clinical trials across cancer, metabolic disease, neurology, immune function, and more.
"Peptides" is a structural category — like saying "proteins." The differences in mechanism, target, and risk between individual peptides are as large as between any other drug classes.
The gray market is the whole story
Two separate worlds exist. Conflating FDA-approved therapeutics with gray-market research chemicals is the most common mistake in this space.
FDA-approved peptides: legal, prescription, well-studied. Compounded/research peptides: a separate, evolving regulatory category. CP covers mechanism and evidence — not sourcing.

Peptides are real. So is finding the right protocol.

Build your stack →
The bigger picture
What the industry data actually shows
For those who want more than headlines — here's what the market, the clinical pipeline, and the regulators are actually doing.
Market scale

One of the fastest-growing categories in modern medicine

$52B–$87B
peptide therapeutics market size in 2025
10%
of all new FDA drug approvals are now peptides — up from low single digits a decade ago
1 in 8
Americans has already used a GLP-1 agonist — a peptide-class drug

GLP-1 agonists — drugs like Ozempic and Wegovy — are projected to reach $100 billion in annual sales by 2030, roughly 1% of US GDP, from a single peptide sub-class. That's not a niche market. That's mainstream medicine moving fast.

See what's in our curated peptide library →
Clinical pipeline

The pipeline is accelerating, not slowing

  • 150+ peptides currently in active clinical trials across cancer, metabolic disease, neurology, and immune function
  • 400–600 peptides in preclinical development — the next generation of approvals is already in the pipeline
  • 300+ GLP-1 receptor drugs in active development — the metabolic disease pipeline alone dwarfs most drug categories
  • 9 peptide and oligonucleotide drugs approved by the FDA in 2023 alone — a pace that "dwarfs the previous two decades combined"
Regulatory landscape

The rules are changing — here's what that actually means

The peptide regulatory picture is legitimately complex. Understanding it clearly is what separates good information from bad.

~102 FDA-approved peptide drugs — therapeutic peptides with established safety and efficacy data, approved for specific medical conditions. These are well inside mainstream medicine.
2023: The FDA moved 19 popular compounded peptides to Category 2, restricting licensed pharmacies from preparing them due to unresolved safety questions.
Feb 2026: HHS Secretary RFK Jr. announced ~14 of those peptides being moved back to Category 1 — restoring legal access through licensed compounding pharmacies with a doctor's prescription.
Important distinction: Category 1 (compoundable with prescription) is not the same as FDA approval. Category 1 means a licensed pharmacy can prepare it. FDA approval means clinical trials have established safety and efficacy for a specific condition. These are different designations — conflating them is a common source of confusion.

Compound Protocol covers mechanism of action and evidence for each peptide. We don't advise on sourcing. Always work with a licensed healthcare provider.

Not sure where you stand? The assistant can help you make sense of it.

Ask the assistant →
Now you know the picture

Here's how to find your protocol

Peptides work when they're matched to the right goal, stacked thoughtfully, and understood clearly. That's what CP is built for.

Build my protocol Browse peptides